< BACK iPROLEPSIS 7th Plenary Meeting in Lisbon Dec 12, 2025 Partners met to review progress and next steps The iPROLEPSIS consortium held its 7th Plenary Meeting on 9–10 December 2025 in Lisbon, Portugal , organised by the Sociedade Portuguesa de Reumatologia (SPR) and hosted at NOVA Medical School . Partners joined on site and remotely for two days of focused discussions on project progress, upcoming study deployments, and priorities for the next phase of the project. Reviewing progress and open scientific issues The first day of the meeting focused on reviewing overall project progress and aligning partners on key scientific and technical developments. Updates were shared across multiple work packages, covering advances in digital phenotyping , data harmonisation , and system development . Dedicated sessions addressed open issues related to digital phenotyping methodologies and data analysis, while partners also discussed progress on data harmonisation activities supporting the project’s clinical studies. An External Advisory Board session provided valuable scientific and strategic feedback on project progress, ongoing work, and next steps. The day included a tour of NOVA Medical School facilities , offering participants insight into the host institution’s research environment. Clinical studies, ecosystem updates, and coordination The second day focused on updates from the project’s clinical studies , including IDBV, PPIDC, MOJMI, and PDPID , with detailed discussions on timelines, technical readiness, and preparations for upcoming deployments. Partners also reviewed progress on the iPROLEPSIS ecosystem, including mobile applications, data management systems, and orchestration components. Coordination, ethics, dissemination, exploitation, and regulatory planning activities were discussed, helping to define clear priorities for the months ahead. Moving forward The meeting concluded with a summary of agreed actions and priorities for the next project phase. Partners will now focus on advancing preparations for the deployment of clinical studies, addressing open technical and methodological issues, strengthening coordination across the ecosystem, and continuing dissemination, exploitation, and regulatory planning activities. Consorcio_iPROLEPSIS20251209143206.jpg 2.jpg IMG_0254.jpg Consorcio_iPROLEPSIS20251209143206.jpg 1/9 PREVIOUS NEXT

< BACK State-of-the-art analysis and datasets landscape Nov 6, 2023 Initial review, focusing on the state-of-the-art literature and existing datasets in the field of PsA Psoriatic arthritis is a chronic immune-mediated inflammatory arthritis occurring in patients with PsO. The disease manifestation can be heterogeneous between subjects, and the resulting musculoskeletal impairment can interfere with physical function as well as the quality of life of patients. In a collaborative effort, the iPROLEPSIS partners completed an initial extensive review, focusing on the state-of-the-art literature and existing datasets in the field of PsA, with a special focus on flare dynamics. The primary goal was to enhance the understanding of PsA by investigating disease symptoms, factors associated with flares, and markers for disease development and monitoring. The insights gained from the literature will provide background for various aspects of iPROLEPSIS research, such as investigating PsA inflammation drivers and monitoring, developing the iPROLEPSIS digital health ecosystem for personalised preventive care, and conducting clinical studies. Moreover, various multi-source datasets have been identified that can potentially yield valuable information for the discovery of PsA inflammation drivers and the development of novel digital biomarkers and predictive models for disease monitoring and progression prognosis. The identified datasets will be assessed for relevancy and usability, retrieved, harmonised and curated. These datasets and predictive models will contribute to the research on PsA monitoring and inflammation drivers. In addition, the identified existing datasets will also guide the development of the Lifestyle AI-driven recommendation system and the Serious Games. The key takeaways are: Fatigue, pain and stiffness are commonly reported symptoms in PsA Flare may be triggered by alterations in mood, stress, sleep, bowel movements, and environmental factors Flare may affect mood, stress, sleep, bowel movements, physical activity and fine motor skills Certain symptoms of PsA may also trigger or be triggered by flare Clinical measurements of PsA symptoms and hypothesized flare associated factors, mainly include questionnaires The use of smartphone and wearables to monitor physical activity (mainly through accelerometer data), fine motor skills (through keystroke dynamics), heart rate, heart rate variability have also shown potential to measure PsA symptoms and hypothesized flare associated factors Electrography techniques can also be used in the assessment of certain symptoms and flare associated factors Genetic factors may contribute to development of PsA, pain perception and response to treatment. Gut microbiome may be involved in PsA. MCs in skin are suggested to play a role in skin inflammation Monitoring of PsA can be achieved through clinical examination for inflamed joints, enthesitis dactylitis, nail and skin and subsequent calculation of relative indices and composite scores Imaging-based approaches including images obtained from smartphones and optoacoustics represent a complementary or alternative approach to clinical assessment Data-driven models can serve to find predictive relations even when the underlying mechanisms are poorly understood or are too complex. Recommendations and SGs present a potential approach to modify and improve diet and physical activity Besides diet and physical activity, SGs can also address other aspects of disease, including medication adherence, social support, cognition, breathing, biological and neural function OMOP CDM was opted to be used for standardising the datasets Future steps include an update on state-of-the-art literature and measurement tools on the topics covered by initial research and the identification of new datasets that could be relevant for data-driven models. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK The miPROLEPSIS Joint Landmarker App Now Available for Android Devices on Google Play Store Sep 25, 2024 A New Tool for Assessing Physical Function in Psoriatic Arthritis As of 25 September 2024, the miPROLEPSIS Joint Landmarker app is available for Android devices on the Google Play Store. This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. miPROLEPSIS Joint Landmarker - Apps on Google Play 1/1 PREVIOUS NEXT

< BACK Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Jun 27, 2024 Enhancing Mobility and Quality of Life through Agile Co-Designed Exergames for Psoriatic Arthritis We are pleased to announce our latest study, "Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes", presented at PETRA 2024. This research, a part of the Horizon Europe iPROLEPSIS project, focuses on creating Exergames to improve physical activity and well-being for individuals with Psoriatic Arthritis. Abstract Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read more: https://dl.acm.org/doi/10.1145/3652037.3663939 Developing Exergames for Psoriatic Arthritis using Agile .pdf Download PDF • 1.70MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at SportEx during ECSS 2026 Aug 18, 2026 Connecting iPROLEPSIS with the sport science community The European Conference of Sports Science (ECSS) 2026 took place in Lausanne, Switzerland, from 7 to 10 July 2026. As part of the event, SportEx , the official exhibition of ECSS, brought together companies from around the world to showcase innovations in sport science, including wearable technologies, physiological measurement systems, biomechanics, and software solutions. iPROLEPSIS was represented at SportEx by project partner PLUX. This participation helped increase the project’s visibility within the wider sport science community and among stakeholders interested in innovative technologies and digital health. PLUX also showcased its work in biosignal acquisition and wearable technologies, areas closely related to the development of innovative digital health solutions within iPROLEPSIS. IProlepsis 2.jpeg Conference overview 2.jpg Booth 3.jpeg IProlepsis 2.jpeg 1/3 PREVIOUS NEXT

Join iProlepsis project for the psoriatic arthritis community. Share your experience, expertise and observations, observations Community Information will be available soon.

< BACK iPROLEPSIS Website Goes Live Mar 27, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Federated Learning Aggregation based on Weight Distribution Analysis Oct 4, 2023 Enhancing Federated Learning: Leveraging Weight Distribution Analysis for Superior Aggregation Federated learning has recently been proposed as a solution to the problem of using private or sensitive data for training a central deep model, without exchanging the local data. In federated learning, local models are trained on the client side using the available data, while a server is responsible for aggregating the weights of these models into a global model. However, the traditional weight averaging approach does not take into consideration the importance of the different weights for the performance of a model. To this end, this work proposes a novel federated learning weight aggregation method that estimates the statistical distance of each client's parameters from the Gaussianity, and weighs the contribution of each client to the global model accordingly so that the most significant information is retained and enhanced. To create an accurate global model, a complex weighted averaging of the parameters of clients' models at the layer level is performed, considering as low quality the parameters following the Gaussian distribution. The proposed method can be employed to both convolutional and linear layers and it is based on the notion that parameters following a Gaussian distribution do not significantly affect the output of a model. Experiments with different network architectures and a comparison with a plethora of state-of-the-art approaches on three well-known image classification datasets demonstrate the superiority of the proposed method for federated learning weight aggregation. Read the full publication: https://www.researchgate.net/publication/374440973_Federated_Learning_Aggregation_based_on_Weight_Distribution_Analysis 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the 15th Portuguese Rheumatology Congress Oct 27, 2023 iPROLEPSIS project and iPROLEPSIS-PDPID study presented at the 15th Portuguese Rheumatology Congress On October 27, 2023, the Portuguese Society of Rheumatology (SPR) , a dedicated partner of iPROLEPSIS , took the stage at the 15th Portuguese Rheumatology Congress (XXV Congresso Português de Reumatologia) , the event attended by around 700 individuals, mainly rheumatologists and GPs. Cátia Gonçalves, Reuma.pt Study Coordinator, and Ana M. Rodrigues, Reuma.pt National Coordinator and Assistant Professor at NOVA Medical School, provided a comprehensive overview of the iPROLEPSIS project, its goals, and clinical studies. They also introduced the iPROLEPSIS-PDPID study , focusing on PsA digital phenotyping and inflammation drivers. Portuguese Rheumatology centres were invited to participate in the iPROLEPSIS-PDPID study, marking a significant step in advancing our research. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT

< BACK Understanding Enthesitis in Psoriatic Arthritis Oct 7, 2024 iPROLEPSIS presented in the 16th Panhellenic Conference of EPEMY Aristotle University of Thessaloniki presented iPROLEPSIS in the 16th Panhellenic Conference of EPEMY held in Ioannina, Greece, from 3-6 October 2024. The presentation addressed important topics related to nesting, the role of enthesitis in Psoriatic Arthritis and Axial Spondyloarthritis, and the most appropriate treatment approaches for enthesitis and digitalis. This conference focused on inflammatory and autoimmune rheumatic, gastrointestinal, and skin diseases, as well as osteoporosis and osteoarthritis. Individual sessions covered Covid-19, cancer, neurological syndromes, and co-morbidities. The event emphasised clinically applied treatments, with interactive, cross-company tutorials and presentations of research projects from domestic centers, which were awarded for their contributions. Read more about the conference here . 1/1 PREVIOUS NEXT

< BACK Understanding Patient Perspectives on Digital Biomarkers for Psoriatic Arthritis Nov 28, 2024 A new study explores opportunities and challenges in using digital biomarkers for Psoriatic Arthritis management A recently published study, Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers , examines how patients with Psoriatic Arthritis (PsA) perceive the use of digital biomarkers (dBMs) in managing their condition. With the increasing use of wearables like smartphones and smartwatches, there is growing interest in utilizing these tools to track physiological and behavioral data in everyday life. This study, involving 27 PsA patients across six focus groups, sheds light on the potential benefits and limitations of integrating dBMs into PsA care. Key Insights The study identified three main areas of interest: Opportunities: Patients saw value in using digital biomarkers to track early signs of disease flare-ups and monitor symptoms over time. Disease Activity Mapping: Participants highlighted the importance of using a broad range of data points to reflect the complexity of PsA symptoms. Barriers: Concerns about privacy, data security, and maintaining strong connections with healthcare providers were key considerations for patients. Relevance to iPROLEPSIS The findings align with iPROLEPSIS’s goal of integrating patient-centered digital health tools into chronic disease management. This study offers important guidance on ensuring digital health innovations address real-world patient needs while maintaining trust and usability. e004699.full .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Insights from iPROLEPSIS 4th Plenary meeting Jul 3, 2024 iPROLEPSIS Plenary Meeting 2024 Recap The 4th iPROLEPSIS plenary meeting took place on 1-2 July 2024 in Munich, Germany, drawing partners from across Europe. The focus was on discussing progress updates and planning future actions towards developing a novel personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). Agenda included: WP overviews, updates and planning next steps General Assembly & External Advisory Board sessions Workshop on : - IDBV (Inflammation digital biomarkers validation study) study: Overview of outcomes, data collection decisions, next steps; - PPIDC (Prevention of PsA inflammation through digital care: an intervention study) study: Objectives, cohort characteristics, study design. WP3 research activities and upcoming deliverables; - iPROLEPSIS ecosystem co-creation, usage scenarios identification, requirements definition; - Serious games co-creation: Introduction to iPROLEPSIS Games app, demonstrations, interactive feedback session. Special Acknowledgment: Gratitude to our patient partners who joined the Serious Games co-creation workshop online and provided valuable insights, ensuring our solutions are truly patient-centric. 1/10 PREVIOUS NEXT